|
1
|
Frame MC: Src in cancer: Deregulation and
consequences for cell behaviour. Biochim Biophys Acta.
1602:114–130. 2002.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ishizawar R and Parsons SJ: c-Src and
cooperating partners in human cancer. Cancer Cell. 6:209–214.
2004.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Summy JM and Gallick GE: Src family
kinases in tumor progression and metastasis. Cancer Metastasis Rev.
22:337–358. 2003.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Irby RB and Yeatman TJ: Role of Src
expression and activation in human cancer. Oncogene. 19:5636–5642.
2000.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yeatman TJ: A renaissance for SRC. Nat Rev
Cancer. 4:470–480. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Kim LC, Song L and Haura EB: Src kinases
as therapeutic targets for cancer. Nat Rev Clin Oncol. 6:587–595.
2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Krishnan H, Miller WT and Goldberg GS: SRC
points the way to biomarkers and chemotherapeutic targets. Genes
Cancer. 3:426–435. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Brown MT and Cooper JA: Regulation,
substrates and functions of src. Biochim Biophys Acta.
1287:121–149. 1996.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Playford MP and Schaller MD: The interplay
between Src and integrins in normal and tumor biology. Oncogene.
23:7928–7946. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hakak Y and Martin GS: Ubiquitin-dependent
degradation of active Src. Curr Biol. 9:1039–1042. 1999.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Laszlo GS and Cooper JA: Restriction of
Src activity by Cullin-5. Curr Biol. 19:157–162. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Okada M, Nada S, Yamanashi Y, Yamamoto T
and Nakagawa H: CSK: A protein-tyrosine kinase involved in
regulation of src family kinases. J Biol Chem. 266:24249–24252.
1991.PubMed/NCBI
|
|
13
|
Ingley E: Src family kinases: Regulation
of their activities, levels and identification of new pathways.
Biochim Biophys Acta. 1784:56–65. 2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rous P: Transmission of a malignant new
growth by means of a cell-free filtrate. J Amer Med Assoc. 56:198.
1911.
|
|
15
|
Rous P: A sarcoma of the fowl
transmissible by an agent from the tumor cells. J Exp Med.
13:397–411. 1911.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bittner JJ: The Milk-influence of breast
tumors in mice. Science. 95:462–463. 1942.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gross L: ‘Spontaneous’ leukemia developing
in C3H mice following inoculation in infancy, with AK-leukemic
extracts, or AK-embrvos. Proc Soc Exp Biol Med. 76:27–32.
1951.PubMed/NCBI
|
|
18
|
Shope RE and Hurst EW: Infectious
papillomatosis of rabbits: With a note on the histopathology. J Exp
Med. 58:607–624. 1933.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sweet BH and Hilleman MR: The vacuolating
virus, S.V.40. Proc Soc Exp Biol Med. 105:420–427. 1960.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Epstein MA, Achong BG and Barr YM: Virus
particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet.
1:702–703. 1964.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kurth R and Bannert N: Beneficial and
detrimental effects of human endogenous retroviruses. Int J Cancer.
126:306–314. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Boveri T: Zur Frage der Entstehung
maligner tumoren. Gustav Fischer, Jena, 1914 (In German).
|
|
23
|
Conney AH, Miller EC and Miller JA: The
metabolism of methylated aminoazo dyes. V. Evidence for induction
of enzyme synthesis in the rat by 3-methylcholanthrene. Cancer Res.
16:450–459. 1956.PubMed/NCBI
|
|
24
|
Cook JW, Hewett CL and Hieger I: 106. The
isolation of a cancer-producing hydrocarbon from coal tar. Parts I,
II, and III. J Chemical Soc (Resumed). 395–405. 1933.
|
|
25
|
Miller EC and Miller JA: The presence and
significance of bound aminoazo dyes in the livers of rats fed
para-dimethylaminoazobenzene. Cancer Res. 7:468–480. 1947.
|
|
26
|
Pott P: Chirurgical observations relative
to the cataract, the polypus of the nose, the cancer of the
scrotum, the different kinds of ruptures, and the mortification of
the toes and feet. Carnegy TJ for Hawes L, Clarke W and Collins R,
London, 1775.
|
|
27
|
Yamagiwa K and Ichikawa K: Experimental
study of the pathogenesis of carcinoma. CA Cancer J Clin.
27:174–181. 1977.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Temin HM and Rubin H: Characteristics of
an assay for rous sarcoma virus and rous sarcoma cells in tissue
culture. Virology. 6:669–688. 1958.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Duesberg PH and Vogt PK: Differences
between ribonucleic acids of transforming and nontransforming avian
tumor viruses. Proc Natl Acad Sci USA. 67:1673–1680.
1970.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Martin GS: Rous sarcoma virus: A function
required for maintenance of transformed state. Nature.
227:1021–1023. 1970.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Toyoshima K and Vogt PK: Temperature
sensitive mutants of an avian sarcoma virus. Virology. 39:930–931.
1969.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Crawford LV and Crawford EM: Properties of
rous sarcoma virus purified by density gradient centrifugation.
Virology. 13:227–232. 1961.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Baltimore D: Viral Rna-Dependent DNA
Polymerase-Rna-Dependent DNA polymerase in virions of rna tumour
viruses. Nature. 226:1209–1211. 1970.
|
|
34
|
Temin HM and Mizutani S: RNA-dependent DNA
polymerase in virions of Rous sarcoma virus. Nature. 226:1211–1213.
1970.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ali M and Baluda MA: Synthesis of avian
oncornavirus DNA in infected chicken cells. J Virol. 13:1005–1013.
1974.PubMed/NCBI
|
|
36
|
Baluda MA: Widespread presence, in
chickens, of DNA complementary to the RNA genome of avian leukosis
viruses. Proc Natl Acad Sci USA. 69:576–580. 1972.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hayward WS and Hanafusa H: Detection of
avian tumor virus RNA in uninfected chicken embryo cells. J Virol.
11:157–167. 1973.PubMed/NCBI
|
|
38
|
Stehelin D, Varmus HE, Bishop JM and Vogt
PK: DNA related to the transforming gene(s) of avian sarcoma
viruses is present in normal avian DNA. Nature. 260:170–173.
1976.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Baluda MA and Drohan WN: Distribution of
deoxyribonucleic acid complementary to the ribonucleic acid of
avian myeloblastosis virus in tissues of normal and tumor-bearing
chickens. J Virol. 10:1002–1009. 1972.PubMed/NCBI
|
|
40
|
Hanafusa T, Hanafusa H and Miyamoto T:
Recovery of a new virus from apparently normal chick cells by
infection with avian tumor viruses. Proc Natl Acad Sci USA.
67:1797–1803. 1970.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Perucho M, Goldfarb M, Shimizu K, Lama C,
Fogh J and Wigler M: Human-tumor-derived cell lines contain common
and different transforming genes. Cell. 27:467–476. 1981.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Shih C, Padhy LC, Murray M and Weinberg
RA: Transforming genes of carcinomas and neuroblastomas introduced
into mouse fibroblasts. Nature. 290:261–264. 1981.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Shih C, Shilo BZ, Goldfarb MP, Dannenberg
A and Weinberg RA: Passage of phenotypes of chemically transformed
cells via transfection of DNA and chromatin. Proc Natl Acad Sci
USA. 76:5714–5718. 1979.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Reddy EP, Reynolds RK, Santos E and
Barbacid M: A point mutation is responsible for the acquisition of
transforming properties by the T24 human bladder carcinoma
oncogene. Nature. 300:149–152. 1982.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Tabin CJ, Bradley SM, Bargmann CI,
Weinberg RA, Papageorge AG, Scolnick EM, Dhar R, Lowy DR and Chang
EH: Mechanism of activation of a human oncogene. Nature.
300:143–149. 1982.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Raju TN: The Nobel Chronicles. 1989: John
Michael Bishop (b 1936) and Harold Eliot Varmus (b 1939). Lancet.
355(1106)2000.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Temin HM: Origin of retroviruses from
cellular moveable genetic elements. Cell. 21:599–600.
1980.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Jove R and Hanafusa H: Cell transformation
by the viral src oncogene. Annu Rev Cell Biol. 3:31–56.
1987.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Frame MC: Newest findings on the oldest
oncogene; how activated src does it. J Cell Sci. 117:989–998.
2004.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Oneyama C and Okada M: MicroRNAs as the
fine-tuners of Src oncogenic signalling. J Biochem. 157:431–438.
2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Mamane Y, Petroulakis E, LeBacquer O and
Sonenberg N: mTOR, translation initiation and cancer. Oncogene.
25:6416–6422. 2006.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Wullschleger S, Loewith R and Hall MN: TOR
signaling in growth and metabolism. Cell. 124:471–484.
2006.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Oneyama C, Ikeda J, Okuzaki D, Suzuki K,
Kanou T, Shintani Y, Morii E, Okumura M, Aozasa K and Okada M:
MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor
growth induced by Src-related oncogenic pathways. Oncogene.
30:3489–3501. 2011.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Doghman M, El Wakil A, Cardinaud B, Thomas
E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP
and Lalli E: Regulation of insulin-like growth factor - mammalian
target of rapamycin signaling by microRNA in childhood
adrenocortical tumors. Cancer Res. 70:4666–4675. 2010.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Fornari F, Milazzo M, Chieco P, Negrini M,
Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L and Gramantieri
L: miR-199a-3p regulates mTOR and c-Met to influence the
doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res.
70:5184–5193. 2010.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Hannigan G, Troussard AA and Dedhar S:
Integrin-linked kinase: A cancer therapeutic target unique among
its ILK. Nat Rev Cancer. 5:51–63. 2005.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Hannigan GE, Leung-Hagesteijn C,
Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC and Dedhar
S: Regulation of cell adhesion and anchorage-dependent growth by a
new beta 1-integrin-linked protein kinase. Nature. 379:91–96.
1996.PubMed/NCBI View Article : Google Scholar
|
|
62
|
McDonald PC, Fielding AB and Dedhar S:
Integrin-linked kinase - essential roles in physiology and cancer
biology. J Cell Sci. 121:3121–3132. 2008.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Oneyama C, Morii E, Okuzaki D, Takahashi
Y, Ikeda J, Wakabayashi N, Akamatsu H, Tsujimoto M, Nishida T,
Aozasa K and Okada M: MicroRNA-mediated upregulation of
integrin-linked kinase promotes Src-induced tumor progression.
Oncogene. 31:1623–1635. 2012.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Donadelli M, Dando I, Fiorini C and
Palmieri M: Regulation of miR-23b expression and its dual role on
ROS production and tumour development. Cancer Lett. 349:107–113.
2014.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Azuma K, Tanaka M, Uekita T, Inoue S,
Yokota J, Ouchi Y and Sakai R: Tyrosine phosphorylation of paxillin
affects the metastatic potential of human osteosarcoma. Oncogene.
24:4754–4764. 2005.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Navon R, Wang H, Steinfeld I, Tsalenko A,
Ben-Dor A and Yakhini Z: Novel rank-based statistical methods
reveal microRNAs with differential expression in multiple cancer
types. PLoS One. 4(e8003)2009.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Shi J, Wang S, Zhao E, Shi L, Xu X and
Fang M: Paxillin expression levels are correlated with clinical
stage and metastasis in salivary adenoid cystic carcinoma. J Oral
Pathol Med. 39:548–551. 2010.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Taylor BS, Schultz N, Hieronymus H,
Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva
B, et al: Integrative genomic profiling of human prostate cancer.
Cancer Cell. 18:11–22. 2010.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Majid S, Dar AA, Saini S, Arora S,
Shahryari V, Zaman MS, Chang I, Yamamura S, Tanaka Y, Deng G, et
al: miR-23b represses proto-oncogene Src kinase and functions as
methylation-silenced tumor suppressor with diagnostic and
prognostic significance in prostate cancer. Cancer Res.
72:6435–6446. 2012.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Kokuda R, Watanabe R, Okuzaki D, Akamatsu
H and Oneyama C: MicroRNA.137.mediated Src oncogenic signaling
promotes cancer progression. Genes Cells: Jul 2, 2018 (Epub ahead
of print).
|
|
71
|
Okuzaki D, Yamauchi T, Mitani F, Miyata M,
Ninomiya Y, Watanabe R, Akamatsu H and Oneyama C: c-Src promotes
tumor progression through downregulation of microRNA-129-1-3p.
Cancer Sci. 111:418–428. 2020.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Kennedy S, Clynes M, Doolan P, Mehta JP,
Rani S, Crown J and O'Driscoll L: SNIP/p140Cap mRNA expression is
an unfavourable prognostic factor in breast cancer and is not
expressed in normal breast tissue. Br J Cancer. 98:1641–1645.
2008.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Yu Z, Ye S, Hu G, Lv M, Tu Z, Zhou K and
Li Q: The RAF-MEK-ERK pathway: Targeting ERK to overcome obstacles
to effective cancer therapy. Future Med Chem. 7:269–289.
2015.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Zhou P, Xiong T, Yao L and Yuan J:
MicroRNA-665 promotes the proliferation of ovarian cancer cells by
targeting SRCIN1. Exp Ther Med. 19:1112–1120. 2020.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Cao M, Hou D, Liang H, Gong F, Wang Y, Yan
X, Jiang X, Wang C, Zhang J, Zen K, et al: miR-150 promotes the
proliferation and migration of lung cancer cells by targeting SRC
kinase signalling inhibitor 1. Eur J Cancer. 50:1013–1024.
2014.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Zhao X, Xu Y, Sun X, Ma Y, Zhang Y and
Wang Y, Guan H, Jia Z, Li Y and Wang Y: miR-17-5p promotes
proliferation and epithelial-mesenchymal transition in human
osteosarcoma cells by targeting SRC kinase signaling inhibitor 1. J
Cell Biochem. 120:5495–5504. 2019.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Yang F, Luo LJ, Zhang L, Wang DD, Yang SJ,
Ding L, Li J, Chen D, Ma R, Wu JZ and Tang JH: miR-346 promotes the
biological function of breast cancer cells by targeting SRCIN1 and
reduces chemosensitivity to docetaxel. Gene. 600:21–28.
2017.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Xu X, Wang W, Su N, Zhu X, Yao J, Gao W,
Hu Z and Sun Y: miR-374a promotes cell proliferation, migration and
invasion by targeting SRCIN1 in gastric cancer. FEBS Lett.
589:407–413. 2015.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Ma L, Shao Z and Zhao Y: MicroRNA-374a
promotes pancreatic cancer cell proliferation and epithelial to
mesenchymal transition by targeting SRCIN1. Pathol Res Pract.
215(152382)2019.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Yuan XL, Wen FQ, Chen XW, Jiang XP and Liu
SX: miR-373 promotes neuroblastoma cell proliferation, migration,
and invasion by targeting SRCIN1. Onco Targets Ther. 12:4927–4936.
2019.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269.
2006.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Lin PY, Yu SL and Yang PC: MicroRNA in
lung cancer. Br J Cancer. 103:1144–1148. 2010.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Pal MK, Jaiswar SP, Dwivedi VN, Tripathi
AK, Dwivedi A and Sankhwar P: MicroRNA: A new and promising
potential biomarker for diagnosis and prognosis of ovarian cancer.
Cancer Biol Med. 12:328–341. 2015.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Nada S, Okada M, MacAuley A, Cooper JA and
Nakagawa H: Cloning of a complementary DNA for a protein-tyrosine
kinase that specifically phosphorylates a negative regulatory site
of p60c-src. Nature. 351:69–72. 1991.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Nada S, Yagi T, Takeda H, Tokunaga T,
Nakagawa H, Ikawa Y, Okada M and Aizawa S: Constitutive activation
of Src family kinases in mouse embryos that lack Csk. Cell.
73:1125–1135. 1993.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Mitra SK and Schlaepfer DD:
Integrin-regulated FAK-Src signaling in normal and cancer cells.
Curr Opin Cell Biol. 18:516–523. 2006.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Fincham VJ, Unlu M, Brunton VG, Pitts JD,
Wyke JA and Frame MC: Translocation of Src kinase to the cell
periphery is mediated by the actin cytoskeleton under the control
of the Rho family of small G proteins. J Cell Biol. 135:1551–1564.
1996.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Harris KF, Shoji I, Cooper EM, Kumar S,
Oda H and Howley PM: Ubiquitin-mediated degradation of active Src
tyrosine kinase. Proc Natl Acad Sci USA. 96:13738–13743.
1999.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Reinecke J and Caplan S: Endocytosis and
the Src family of non-receptor tyrosine kinases. Biomol Concepts.
5:143–155. 2014.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Tu C, Ortega-Cava CF, Winograd P, Stanton
MJ, Reddi AL, Dodge I, Arya R, Dimri M, Clubb RJ, Naramura M, et
al: Endosomal-sorting complexes required for transport (ESCRT)
pathway-dependent endosomal traffic regulates the localization of
active Src at focal adhesions. Proc Natl Acad Sci USA.
107:16107–16112. 2010.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Tanaka K, Ito Y, Kajiwara K, Nada S and
Okada M: Ubiquitination of Src promotes its secretion via small
extracellular vesicles. Biochem Biophys Res Commun: Feb 18, 2020
(Epub ahead of print).
|
|
92
|
Ji H, Greening DW, Barnes TW, Lim JW,
Tauro BJ, Rai A, Xu R, Adda C, Mathivanan S, Zhao W, et al:
Proteome profiling of exosomes derived from human primary and
metastatic colorectal cancer cells reveal differential expression
of key metastatic factors and signal transduction components.
Proteomics. 13:1672–1686. 2013.PubMed/NCBI View Article : Google Scholar
|
|
93
|
DeRita RM, Zerlanko B, Singh A, Lu H,
Iozzo RV, Benovic JL and Languino LR: c-Src, insulin-like growth
factor I receptor, G-protein-coupled receptor kinases and focal
adhesion kinase are enriched into prostate cancer cell exosomes. J
Cell Biochem. 118:66–73. 2017.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Imjeti NS, Menck K, Egea-Jimenez AL,
Lecointre C, Lembo F, Bouguenina H, Badache A, Ghossoub R, David G,
Roche S, et al: Syntenin mediates SRC function in exosomal
cell-to-cell communication. Proc Natl Acad Sci USA.
114:12495–12500. 2017.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Hikita T, Kuwahara A, Watanabe R, Miyata M
and Oneyama C: Src in endosomal membranes promotes exosome
secretion and tumor progression. Sci Rep. 9(3265)2019.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Roskoski R Jr: Src protein-tyrosine kinase
structure, mechanism, and small molecule inhibitors. Pharmacol Res.
94:9–25. 2015.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Daud AI, Krishnamurthi SS, Saleh MN,
Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R,
Agarwal S, et al: Phase I study of bosutinib, a src/abl tyrosine
kinase inhibitor, administered to patients with advanced solid
tumors. Clin Cancer Res. 18:1092–1100. 2012.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Moy B, Neven P, Lebrun F, Bellet M, Xu B,
Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, et al: Bosutinib
in combination with the aromatase inhibitor letrozole: A phase II
trial in postmenopausal women evaluating first-line endocrine
therapy in locally advanced or metastatic hormone
receptor-positive/HER2-negative breast cancer. Oncologist.
19:348–349. 2014.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Taylor JW, Dietrich J, Gerstner ER, Norden
AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA,
Giorgio DH, et al: Phase 2 study of bosutinib, a Src inhibitor, in
adults with recurrent glioblastoma. J Neurooncol. 121:557–563.
2015.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Araujo J and Logothetis C: Dasatinib: A
potent SRC inhibitor in clinical development for the treatment of
solid tumors. Cancer Treat Rev. 36:492–500. 2010.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Cortes JE, Kim DW, Pinilla-Ibarz J, Le
Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ,
Talpaz M, et al: A phase 2 trial of ponatinib in Philadelphia
chromosome-positive leukemias. N Engl J Med. 369:1783–1796.
2013.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Ahn JS, Lee KH, Sun JM, Park K, Kang ES,
Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, et al: A randomized, phase
II study of vandetanib maintenance for advanced or metastatic
non-small-cell lung cancer following first-line platinum-doublet
chemotherapy. Lung Cancer. 82:455–460. 2013.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Gridelli C, Novello S, Zilembo N, Luciani
A, Favaretto AG, De Marinis F, Genestreti G, Crino L, Grossi F,
Caffo O, et al: Phase II randomized study of vandetanib plus
gemcitabine or gemcitabine plus placebo as first-line treatment of
advanced non-small-cell lung cancer in elderly patients. J Thorac
Oncol. 9:733–737. 2014.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Sim MW and Cohen MS: The discovery and
development of vandetanib for the treatment of thyroid cancer.
Expert Opin Drug Discov. 9:105–114. 2014.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Gucalp A, Sparano JA, Caravelli J,
Santamauro J, Patil S, Abbruzzi A, Pellegrino C, Bromberg J, Dang
C, Theodoulou M, et al: Phase II trial of saracatinib (AZD0530), an
oral SRC-inhibitor for the treatment of patients with hormone
receptor-negative metastatic breast cancer. Clin Breast Cancer.
11:306–311. 2011.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Laurie SA, Goss GD, Shepherd FA, Reaume
MN, Nicholas G, Philip L, Wang L, Schwock J, Hirsh V, Oza A, et al:
A phase II trial of saracatinib, an inhibitor of src kinases, in
previously-treated advanced non-small-cell lung cancer: The
Princess Margaret Hospital phase II consortium. Clin Lung Cancer.
15:52–57. 2014.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Molina JR, Foster NR, Reungwetwattana T,
Nelson GD, Grainger AV, Steen PD, Stella PJ, Marks R, Wright J and
Adjei AA: A phase II trial of the Src-kinase inhibitor saracatinib
after four cycles of chemotherapy for patients with extensive stage
small cell lung cancer: NCCTG trial N-0621. Lung Cancer.
85:245–250. 2014.PubMed/NCBI View Article : Google Scholar
|
|
108
|
U.S. National Library of Medicine:
https://clinicaltrials.gov/.
https://clinicaltrials.gov.
Accessed July 1, 2020.
|
|
109
|
U.S. National Library of Medicine: Phase I
Trial of Afatinib (BIBW 2992) and dasatinib in non-small cell lung
cancer (NSCLC). https://clinicaltrials.gov/
Identifier: NCT01999985. https://ClinicalTrials.gov/show/NCT01999985].
Accessed June 14, 2019.
|
|
110
|
U.S. National Library of Medicine:
Dasatinib in combination with trastuzumab and paclitaxel in first
line treatment of Her2-Positive MBC patients. https://clinicaltrials.gov/
Identifier: NCT01306942. https://ClinicalTrials.gov/show/NCT01306942].
Accessed September 9, 2019.
|
|
111
|
U.S. National Library of Medicine: Trial
of dasatinib plus ixabepilone in 2nd or 3rd line metastatic breast
cancer. https://clinicaltrials.gov/
Identifier: NCT00924352. https://ClinicalTrials.gov/show/NCT00924352].
Accessed September 29, 2014.
|
|
112
|
U.S. National Library of Medicine: Study
of dasatinib and docetaxel in metastatic hormone refractory
prostate cancer. https://clinicaltrials.gov/
Identifier: NCT00439270. https://ClinicalTrials.gov/show/NCT00439270].
Accessed November 27, 2013.
|
|
113
|
U.S. National Library of Medicine:
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC).
https://clinicaltrials.gov/
Identifier: NCT00826449. https://ClinicalTrials.gov/show/NCT00826449].
Accessed October 21, 2015.
|
|
114
|
U.S. National Library of Medicine: Study
evaluating bosutinib-exemestane combination vs exemestane alone in
post menopausal women with breast cancer. https://clinicaltrials.gov/
Identifier: NCT00793546. https://ClinicalTrials.gov/show/NCT00793546].
Accessed November 5, 2012.
|
|
115
|
U.S. National Library of Medicine: Study
evaluating bosutinib-letrozole combination versus letrozole alone
in post menopausal women with breast cancer. https://clinicaltrials.gov/
Identifier: NCT00880009. https://ClinicalTrials.gov/show/NCT00880009].
Accessed November 5, 2012.
|
|
116
|
U.S. National Library of Medicine: Study
of bosutinib with capecitabine in solid tumors and locally advanced
or metastatic breast cancer. https://clinicaltrials.gov/
Identifier: NCT00959946. https://ClinicalTrials.gov/show/NCT00959946].
Accessed February 22, 2013.
|
|
117
|
U.S. National Library of Medicine: A
Multicenter Phase 3, Open-label study of bosutinib versus imatinib
in adult patients with newly diagnosed chronic phase chronic
myelogenous leukemia. https://clinicaltrials.gov/
Identifier: NCT02130557. https://ClinicalTrials.gov/show/NCT02130557].
Accessed November 14, 2018.
|
|
118
|
U.S. National Library of Medicine: AZD0530
Phase II study in patients with advanced ovarian cancer. https://clinicaltrials.gov/
Identifier: NCT00610714. https://ClinicalTrials.gov/show/NCT00610714].
Accessed September 20, 2011.
|
|
119
|
U.S. National Library of Medicine:
Saracatinib and paclitaxel in platinum-resistant ovarian cancer.
https://clinicaltrials.gov/
Identifier: NCT01196741. https://ClinicalTrials.gov/show/NCT01196741].
Accessed May 5, 2015.
|
